Biomerica, Inc. announced a major enhancement to its inFoods IBS platform, making the test directly available to U.S. consumers through infoodsibs.com. This new direct-to-consumer model allows individuals to order the test and collect a sample from their home, with a licensed physician remotely authorizing the test. This approach offers a convenient pathway for patients seeking to manage Irritable Bowel Syndrome (IBS) symptoms such as bloating and gastrointestinal pain.
The inFoods IBS test provides a personalized and non-invasive solution by identifying specific foods that may trigger a patient's symptoms, allowing for tailored dietary changes. A recent double-blinded, placebo-controlled, multicenter clinical study demonstrated that the inFoods IBS test significantly improved key IBS symptoms, including Abdominal Pain Intensity (API) and bloating. This offers a natural management approach without the side effects commonly associated with drug therapies.
IBS affects an estimated 1 in 20 Americans and contributes to approximately $10 billion in annual direct medical costs. By offering direct access, Biomerica aims to provide new hope for millions of IBS sufferers who struggle to find effective treatments. The company believes this platform addresses a significant unmet medical need by providing a tailored approach to treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.